{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:26:33Z","timestamp":1792517193479,"version":"4.5.0"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Non-alcoholic fatty liver disease (NAFLD), now known as metabolic-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, with a prevalence of 38%. In these patients, cardiovascular disease (CVD) is the number one cause of mortality rather than liver disease. Liver abnormalities\n                    <jats:italic>per se<\/jats:italic>\n                    due to MASLD contribute to risk factors such as dyslipidemia and obesity and increase CVD incidents. In this review we discuss hepatic pathophysiological changes the liver of MASLD leading to cardiovascular risks, including liver sinusoidal endothelial cells, insulin resistance, and oxidative stress with a focus on glutathione metabolism and function. In an era where there is an increasingly robust recognition of what causes CVD, such as the factors included by the American Heart Association in the recently developed PREVENT equation, the inclusion of liver disease may open doors to how we approach treatment for MASLD patients who are at risk of CVD.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2024.1469492","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:35:34Z","timestamp":1727742934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress"],"prefix":"10.3389","volume":"11","author":[{"given":"Erika T.","family":"Minetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Hamburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B3","first-page":"e54","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume-title":"J Hepatol.","author":"Song","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metab Clin Exp"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/gutjnl-2016-311854","article-title":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study","volume":"66","author":"Sinn","year":"2017","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/HJH.0000000000000532","article-title":"Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk","volume":"33","author":"Aneni","year":"2015","journal-title":"J Hypertens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jgh.12643","article-title":"Clinical association between non-alcoholic fatty liver disease and the development of hypertension","volume":"29","author":"Ryoo","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-14-166","article-title":"Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease","volume":"14","author":"Haflidadottir","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s40618-022-01792-9","article-title":"Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD","volume":"45","author":"Ciardullo","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0142937","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2015","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.diabet.2023.101468","article-title":"Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke","volume":"49","author":"Chen","year":"2023","journal-title":"Diabetes Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s10620-019-05986-9","article-title":"Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany","volume":"65","author":"Labenz","year":"2020","journal-title":"Dig Dis Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/imj.13549","article-title":"Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes","volume":"47","author":"Zou","year":"2017","journal-title":"Intern Med J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/jgh.14856","article-title":"Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study","volume":"35","author":"Sinn","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jceh.2021.08.016","article-title":"Diagnosis and management of cirrhotic cardiomyopathy","volume":"12","author":"Kaur","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.3748\/wjg.v21.i41.11502","article-title":"Cirrhotic cardiomyopathy","volume":"21","author":"Ruiz-Del-Arbol","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2017.02.005","article-title":"Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke","volume":"260","author":"Kim","year":"2017","journal-title":"Atherosclerosis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCRESAHA.121.319059","article-title":"Nonalcoholic fatty liver disease: an emerging driver of cardiac arrhythmia","volume":"128","author":"Chen","year":"2021","journal-title":"Circ Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.32728","article-title":"The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study","volume":"77","author":"Xie","year":"2023","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3350\/cmh.2020.0137","article-title":"Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease","volume":"26","author":"Kim","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-023-03586-1","article-title":"The role of anti-diabetic drugs in NAFLD. Have we found the holy grail? A narrative review","volume":"80","author":"Zachou","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells\u2014gatekeepers of hepatic immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/labinvest.2015.95","article-title":"Pivotal role of liver sinusoidal endothelial cells in NAFLD\/NASH progression","volume":"95","author":"Miyao","year":"2015","journal-title":"Lab Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e115005","DOI":"10.1371\/journal.pone.0115005","article-title":"Formation of fenestrae in murine liver sinusoids Depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage","volume":"9","author":"Herrnberger","year":"2014","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0022-2275(20)34932-4","article-title":"Hepatic uptake of chylomicron remnants","volume":"38","author":"Cooper","year":"1997","journal-title":"J Lipid Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jhep.2023.08.023","article-title":"Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux","volume":"79","author":"Chen","year":"2023","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0037-1617455","article-title":"Liver sinusoidal endothelial cell: an update","volume":"37","author":"DeLeve","year":"2017","journal-title":"Semin Liver Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2012.06.005","article-title":"Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians","volume":"223","author":"Thakur","year":"2012","journal-title":"Atherosclerosis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cells11162511","article-title":"Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review","volume":"11","author":"Nasiri-Ansari","year":"2022","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1152\/ajpgi.00017.2004","article-title":"Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation","volume":"287","author":"DeLeve","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"Petersen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3390\/cells10082035","article-title":"Severe hepatic insulin resistance induces vascular dysfunction: improvement by liver-specific insulin receptor isoform A gene therapy in a murine diabetic model","volume":"10","author":"G\u00f3mez-Hern\u00e1ndez","year":"2021","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2010.03.01","article-title":"Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice","volume":"11","author":"Rask-Madsen","year":"2010","journal-title":"Cell Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0163-7827(01)00010-8","article-title":"Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes","volume":"40","author":"Shimano","year":"2001","journal-title":"Prog Lipid Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.freeradbiomed.2009.07.016","article-title":"SREBP-1c in nonalcoholic fatty liver disease induced by western-type high-fat diet plus fructose in rats","volume":"47","author":"Aragno","year":"2009","journal-title":"Free Radic Biol Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/nu12051316","article-title":"Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD","volume":"12","author":"Worm","year":"2020","journal-title":"Nutrients"},{"key":"B60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2006-927368","article-title":"Lipid metabolism in the liver","volume":"45","author":"Canbay","year":"2007","journal-title":"Z Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2008.08.068","article-title":"Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells","volume":"375","author":"Sekiya","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1617805","DOI":"10.1155\/2020\/1617805","article-title":"Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Gonzalez","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1089\/ars.2005.7.1040","article-title":"The molecular basis for oxidative stress-induced insulin resistance","volume":"7","author":"Evans","year":"2005","journal-title":"Antioxid Redox Signal."},{"key":"B65","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.metabol.2006.01.003","article-title":"Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus","volume":"55","author":"Bravi","year":"2006","journal-title":"Metab Clin Exp"},{"key":"B66","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.freeradbiomed.2017.12.019","article-title":"The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease","volume":"115","author":"Matsumoto","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41467-017-02325-2","article-title":"Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex","volume":"8","author":"Kim","year":"2017","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/j.gastro.2015.04.009","article-title":"Hepatocyte NADPH oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice","volume":"149","author":"Bettaieb","year":"2015","journal-title":"Gastroenterology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e162533","DOI":"10.1172\/JCI162533","article-title":"Mitochondria- and NOX4-dependent antioxidant defense mitigates progression to nonalcoholic steatohepatitis in obesity","volume":"134","author":"Greatorex","year":"2024","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jcmgh.2017.11.016","article-title":"Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2)","volume":"5","author":"Sharma","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2022.06.226","article-title":"Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2","volume":"188","author":"Bathish","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/ijms25021314","article-title":"Mitochondrial glutathione in cellular redox homeostasis and disease manifestation","volume":"25","author":"Chen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1042\/CS20030285","article-title":"Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients","volume":"106","author":"Videla","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5152\/tjg.2016.16106","article-title":"Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease","volume":"27","author":"K\u00f6ro\u01e7lu","year":"2016","journal-title":"Turk J Gastroenterol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000320552","article-title":"Long-term high-fat-diet feeding impairs mitochondrial biogenesis in liver of male and female rats","volume":"26","author":"Nadal-Casellas","year":"2010","journal-title":"Cell Physiol Biochem"},{"key":"B77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-1007167","article-title":"Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine","volume":"18","author":"Ookhtens","year":"1998","journal-title":"Semin Liver Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox10030364","article-title":"Changes in glutathione content in liver diseases: an update","volume":"10","author":"Vairetti","year":"2021","journal-title":"Antioxidants"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1124275","DOI":"10.3389\/fmed.2023.1124275","article-title":"Glutathione: pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease","volume":"10","author":"Santacroce","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.00","article-title":"Plasma metabolomic profile in non-alcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"","journal-title":"Metab Clin Exp"},{"key":"B81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/10715760701836821","article-title":"Plasma glutathione levels are independently associated with gamma-glutamyltransferase activity in subjects with cardiovascular risk factors","volume":"42","author":"Sedda","year":"2008","journal-title":"Free Radic Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/nu15040944","article-title":"Dietary supplements potentially target plasma glutathione levels to improve cardiometabolic health in patients with diabetes mellitus: a systematic review of randomized clinical trials","volume":"15","author":"Dludla","year":"2023","journal-title":"Nutrients"},{"key":"B83","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/01.ATV.0000251993.20372.40","article-title":"Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study","volume":"27","author":"Lee","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.4049\/jimmunol.1800614","article-title":"Differential activation of hepatic invariant NKT cell subsets plays a key role in progression of nonalcoholic steatohepatitis","volume":"201","author":"Maricic","year":"2018","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/850836","article-title":"Role of NKT cells in the pathogenesis of NAFLD","volume":"2012","author":"Tajiri","year":"2012","journal-title":"Int J Hepatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/hep.31889","article-title":"The emerging role of B cells in the pathogenesis of NAFLD","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jhep.2021.12.012","article-title":"Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease","volume":"76","author":"Govaere","year":"2022","journal-title":"J Hepatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCRESAHA.116.308688","article-title":"Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction","volume":"118","author":"Zhao","year":"2016","journal-title":"Circ Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"B92","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s42255-023-00834-7","article-title":"Human resident liver myeloid cells protect against metabolic stress in obesity","volume":"5","author":"Barreby","year":"2023","journal-title":"Nat Metab"},{"key":"B94","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.redox.2018.01.009","article-title":"Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches","volume":"15","author":"Borrelli","year":"2018","journal-title":"Redox Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/antiox12091680","article-title":"Thioredoxin\/glutaredoxin systems and gut microbiota in NAFLD: interplay, mechanism, and therapeutical potential","volume":"12","author":"Zhu","year":"2023","journal-title":"Antioxidants"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/liv.14899","article-title":"Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease","volume":"41","author":"Lang","year":"2021","journal-title":"Liver Int"},{"key":"B98","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCRESAHA.120.316242","article-title":"Gut microbiota and cardiovascular disease","volume":"127","author":"Witkowski","year":"2020","journal-title":"Circ Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"19076","DOI":"10.1038\/srep19076","article-title":"Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-32584-7","article-title":"Ameliorating effect of probiotic on nonalcoholic fatty liver disease and lipolytic gene expression in rabbits","volume":"13","author":"Aziz","year":"2023","journal-title":"Sci Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2019.09.014","article-title":"Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1","volume":"72","author":"Jiang","year":"2020","journal-title":"J Hepatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"\u00d6nnerhag","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e0277729","DOI":"10.1371\/journal.pone.0277729","article-title":"Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: the Dong-Gu study","volume":"17","author":"Choi","year":"2022","journal-title":"PLoS One"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/dc14-3082","article-title":"Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes","volume":"38","author":"Fer\u0144andez-Real","year":"2015","journal-title":"Diabetes Care"},{"key":"B114","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41420-023-01749-8","article-title":"Programmed cell death in hepatic fibrosis: current and perspectives","volume":"9","author":"Lu","year":"2023","journal-title":"Cell Death Discov"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of non-apoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","first-page":"102131","DOI":"10.1016\/j.redox.2021.102131","article-title":"Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis","volume":"46","author":"Wu","year":"2021","journal-title":"Redox Biol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jceh.2022.03.002","article-title":"Management of portal hypertension","volume":"12","author":"Kulkarni","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0973-6883(11)60127-8","article-title":"Pathophysiology of portal hypertension and its clinical links","volume":"1","author":"Seo","year":"2011","journal-title":"J Clin Exp Hepatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e27969","DOI":"10.7759\/cureus.27969","article-title":"Cirrhotic cardiomyopathy: the interplay between liver and heart","volume":"14","author":"Kalluru","year":"2022","journal-title":"Cureus"},{"key":"B121","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"B122","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0016-5085(00)70180-6","article-title":"Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats","volume":"118","author":"Liu","year":"2000","journal-title":"Gastroenterology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1073\/pnas.94.13.6954","article-title":"Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages","volume":"94","author":"Xia","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B124","doi-asserted-by":"publisher","first-page":"117821","DOI":"10.1016\/j.lfs.2020.117821","article-title":"Molecular mechanisms by which INOS uncoupling can induce cardiovascular dysfunction during sepsis: role of posttranslational modifications (PTMs)","volume":"255","author":"Sharawy","year":"2020","journal-title":"Life Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes\u2014a UK biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B127","first-page":"433","article-title":"PNPLA3 I148M polymorphism in patients with nonalcoholic fatty liver disease, obesity and prediabetes.","volume-title":"J Gastrointestin Liver Dis.","author":"Karamfilova","year":"2019"},{"key":"B128","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","article-title":"PNPLA3 genotype and diabetes identify patients with non-alcoholic fatty liver disease at high risk of incident cirrhosis","volume":"164","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B130","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1323785111","article-title":"TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content","volume":"111","author":"Mahdessian","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B131","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/01.CIR.0000137822.39831.F1","article-title":"Antioxidant vitamin supplements and cardiovascular disease","volume":"110","author":"Kris-Etherton","year":"2004","journal-title":"Circulation"},{"key":"B132","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/MCA.0000000000000187","article-title":"Antioxidants and coronary artery disease: from pathophysiology to preventive therapy","volume":"26","author":"Leopold","year":"2015","journal-title":"Coron Artery Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41598-022-05632-x","article-title":"Associations between dietary antioxidant intakes and cardiovascular disease","volume":"12","author":"Mirmiran","year":"2022","journal-title":"Sci Rep"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antiox7010012","article-title":"Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth?","volume":"7","author":"El Hadi","year":"2018","journal-title":"Antioxidants"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox10020174","article-title":"Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy","volume":"10","author":"Arroyave-Ospina","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.3748\/wjg.v23.i23.4146","article-title":"Antioxidant dietary approach in treatment of fatty liver: new insights and updates","volume":"23","author":"Ferramosca","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","article-title":"Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis","volume":"31","author":"Sun","year":"2020","journal-title":"Cell Metab"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1186582","DOI":"10.3389\/fphar.2023.1186582","article-title":"Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.redox.2015.07.012","article-title":"Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study","volume":"6","author":"Schmitt","year":"2015","journal-title":"Redox Biol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj.CJ-16-0317","article-title":"Redox regulation of ischemic angiogenesis: another aspect of reactive oxygen species","volume":"80","author":"Watanabe","year":"2016","journal-title":"Circ J"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.redox.2017.04.040","article-title":"Redox regulation of ischemic limb neovascularization\u2014what we have learned from animal studies","volume":"12","author":"Matsui","year":"2017","journal-title":"Redox Biol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s12276-017-0013-x","article-title":"Glutathione disulfide sensitizes hepatocytes to TNF\u03b1-mediated cytotoxicity via IKK-\u03b2 S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease","volume":"50","author":"Dou","year":"2018","journal-title":"Exp Mol Med"},{"key":"B146","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.1074\/jbc.M113.520403","article-title":"A redox-resistant sirtuin-1 mutant protects against hepatic metabolic and oxidant stress","volume":"289","author":"Shao","year":"2014","journal-title":"J Biol Chem"},{"key":"B147","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/ars.2016.6716","article-title":"Glutaredoxin-1 deficiency causes fatty liver and dyslipidemia by inhibiting sirtuin-1","volume":"27","author":"Shao","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1042\/BST20140213","article-title":"Regulation of neovascularization by S-glutathionylation via the Wnt5a\/sFlt-1 pathway","volume":"42","author":"Murdoch","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41591-018-0090-y","article-title":"Reducing protein oxidation reverses lung fibrosis","volume":"24","author":"Anathy","year":"2018","journal-title":"Nat Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jnutbio.2010.11.013","article-title":"Redox homeostasis and posttranslational modifications\/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis","volume":"23","author":"Alisi","year":"2012","journal-title":"J Nutr Biochem"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a036137","article-title":"Metabolic role of PTEN in insulin signaling and resistance","volume":"10","author":"Li","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1089\/ars.2019.7963","article-title":"Redox regulation via glutaredoxin-1 and protein S-glutathionylation","volume":"32","author":"Matsui","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"B153","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/antiox11050867","article-title":"Administration of glutaredoxin-1 attenuates liver fibrosis caused by aging and non-alcoholic steatohepatitis","volume":"11","author":"Tsukahara","year":"2022","journal-title":"Antioxidants"},{"key":"B154","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1089\/ars.2020.8254","article-title":"Cardiovascular risk stratification based on oxidative stress for early detection of pathology","volume":"35","author":"Corbacho-Alonso","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"B155","doi-asserted-by":"publisher","first-page":"eaaz2841","DOI":"10.1126\/scitranslmed.aaz2841","article-title":"Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome","volume":"12","author":"Rom","year":"2020","journal-title":"Sci Transl Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.freeradbiomed.2021.07.037","article-title":"Oxidized GAPDH transfers S-glutathionylation to a nuclear protein sirtuin-1 leading to apoptosis","volume":"174","author":"Mustafa Rizvi","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1152\/ajpheart.01162.2006","article-title":"Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system","volume":"292","author":"Berndt","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186803","article-title":"Role of glutaredoxin-1 and glutathionylation in cardiovascular diseases","volume":"21","author":"Burns","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.2337\/dc19-2046","article-title":"Impact of acarbose on incident diabetes and regression to normoglycemia in people with coronary heart disease and impaired glucose tolerance: insights from the ACE trial","volume":"43","author":"Gerstein","year":"2020","journal-title":"Diabetes Care"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/hep.32778","article-title":"Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial","volume":"78","author":"Dellinger","year":"2023","journal-title":"Hepatology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"B164","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"key":"B167","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74\u2005mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u2005mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.2337\/db21-0451","article-title":"SCO-267, a GPR40 full agonist, stimulates islet and gut hormone secretion and improves glycemic control in humans","volume":"70","author":"Nishizaki","year":"2021","journal-title":"Diabetes"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e13767","DOI":"10.1111\/acel.13767","article-title":"Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age","volume":"22","author":"Islam","year":"2023","journal-title":"Aging Cell"},{"key":"B171","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cmet.2021.10.016","article-title":"Nutritional reprogramming of mouse liver proteome is dampened by metformin, resveratrol, and rapamycin","volume":"33","author":"Le Couteur","year":"2021","journal-title":"Cell Metab"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db19-1129","article-title":"Antioxidant effects of N-acetylcysteine prevent programmed metabolic disease in mice","volume":"69","author":"Charron","year":"2020","journal-title":"Diabetes"},{"key":"B173","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B175","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"key":"B176","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1089\/thy.2021.0621","article-title":"Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis","volume":"32","author":"Zhou","year":"2022","journal-title":"Thyroid"},{"key":"B179","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cmet.2020.01.013","article-title":"Targeting hepatic glutaminase 1 ameliorates non-alcoholic steatohepatitis by restoring very-low-density lipoprotein triglyceride assembly","volume":"31","author":"Simon","year":"2020","journal-title":"Cell Metab"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1469492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:35:37Z","timestamp":1727742937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1469492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":182,"alternative-id":["10.3389\/fcvm.2024.1469492"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1469492","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"1469492"}}